LRP1 and stroke disorder: Two aptamers (K18/K32) were found to efficiently inhibit tPA-LRP-1 association and LRP-mediated endocytosis in human astrocytes and vascular endothelial cells, providing a viable strategy to improve the safety of thrombolytic treatment in stroke through co-administration with tPA (Yepes, 2024).